Search hospitals > Nevada > Henderson

Comprehensive Cancer Centers of Nevada - Henderson

Claim this profile
Henderson, Nevada 89052
Global Leader in Cancer
Global Leader in Breast Cancer
Conducts research for Lung Cancer
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Adenocarcinoma
244 reported clinical trials
6 medical researchers
Photo of Comprehensive Cancer Centers of Nevada - Henderson in HendersonPhoto of Comprehensive Cancer Centers of Nevada - Henderson in HendersonPhoto of Comprehensive Cancer Centers of Nevada - Henderson in Henderson

Summary

Comprehensive Cancer Centers of Nevada - Henderson is a medical facility located in Henderson, Nevada. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Adenocarcinoma and other specialties. Comprehensive Cancer Centers of Nevada - Henderson is involved with conducting 244 clinical trials across 357 conditions. There are 6 research doctors associated with this hospital, such as John A. Ellerton, Alan K. Ikeda, Stephani Christensen, MD, and Ramalingam Ratnasabapathy.

Area of expertise

1Cancer
Global Leader
Comprehensive Cancer Centers of Nevada - Henderson has run 80 trials for Cancer. Some of their research focus areas include:
Stage IV
Stage III
Stage I
2Breast Cancer
Global Leader
Comprehensive Cancer Centers of Nevada - Henderson has run 46 trials for Breast Cancer. Some of their research focus areas include:
Stage IV
ER positive
HER2 negative

Top PIs

Clinical Trials running at Comprehensive Cancer Centers of Nevada - Henderson

Breast Cancer
Non-Small Cell Lung Cancer
Lung Cancer
Prostate Cancer
Cancer
Bladder Cancer
Bladder Carcinoma
Gastric Cancer
Renal Cell Carcinoma
Adenocarcinoma
Image of trial facility.

Chemotherapy + Hormone Therapy

for Breast Cancer

This trial is testing if adding additional cancer-fighting drugs to treatments that stop certain body functions is better than just using the treatments that stop those functions alone. It targets younger women with early-stage breast cancer who have a higher risk of dying from the disease. The treatment works by stopping certain body functions and using drugs to kill cancer cells.
Recruiting2 awards Phase 319 criteria
Image of trial facility.

ARV-471

for Breast Cancer

This trial tests a new oral medicine, ARV-471, against an existing injectable treatment, fulvestrant, in people with advanced breast cancer that has spread. Both medicines aim to slow cancer growth by targeting estrogen receptors. ARV-471 is developed as an oral alternative to fulvestrant.
Recruiting2 awards Phase 35 criteria
Image of trial facility.

Mobile Health

for Breast Cancer

This clinical trial compares the use of the connected customized treatment platform (CONCURxP), consisting of using a medication monitoring device called WiseBag along with text message reminders for missed or extra medication events, to enhanced usual care (EUC), where patients only use the WiseBag, to monitor medication adherence in patients with metastatic breast cancer who are taking a CKD4/6 inhibitor. To ensure CDK4/6 inhibitors achieve their full clinical benefit, patients need to take them as prescribed, following a complex treatment schedule. Forgetfulness was the most common reason reported for medication non adherence. Using the WiseBag along with CONCURxP or enhanced usual care may improve medication adherence in patients with metastatic breast cancer who are taking a CKD4/6 inhibitor.
Recruiting1 award N/A10 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Comprehensive Cancer Centers of Nevada - Henderson?
Comprehensive Cancer Centers of Nevada - Henderson is a medical facility located in Henderson, Nevada. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Adenocarcinoma and other specialties. Comprehensive Cancer Centers of Nevada - Henderson is involved with conducting 244 clinical trials across 357 conditions. There are 6 research doctors associated with this hospital, such as John A. Ellerton, Alan K. Ikeda, Stephani Christensen, MD, and Ramalingam Ratnasabapathy.